180 related articles for article (PubMed ID: 38706610)
1. Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers.
Skorupan N; Peer CJ; Zhang X; Choo-Wosoba H; Ahmad MI; Lee MJ; Rastogi S; Sato N; Yu Y; Pegna GJ; Steinberg SM; Kalsi SS; Cao L; Figg WD; Trepel JB; Pastan I; FitzGerald D; Alewine C
Front Oncol; 2024; 14():1386190. PubMed ID: 38706610
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelin.
Hassan R; Alewine C; Mian I; Spreafico A; Siu LL; Gomez-Roca C; Delord JP; Italiano A; Lassen U; Soria JC; Bahleda R; Thomas A; Steinberg SM; Peer CJ; Figg WD; Niederfellner G; Méresse Naegelen V; Pastan I
Cancer; 2020 Nov; 126(22):4936-4947. PubMed ID: 32870522
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic Adenocarcinoma.
Alewine C; Ahmad M; Peer CJ; Hu ZI; Lee MJ; Yuno A; Kindrick JD; Thomas A; Steinberg SM; Trepel JB; Figg WD; Hassan R; Pastan I
Clin Cancer Res; 2020 Feb; 26(4):828-836. PubMed ID: 31792036
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Methotrexate Prevents Primary and Secondary Humoral Immune Responses and Induces Immune Tolerance to a Recombinant Immunotoxin.
King EM; Mazor R; Çuburu N; Pastan I
J Immunol; 2018 Mar; 200(6):2038-2045. PubMed ID: 29431691
[TBL] [Abstract][Full Text] [Related]
5. Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.
Pegna GJ; Lee MJ; Peer CJ; Ahmad MI; Venzon DJ; Yu Y; Yuno A; Steinberg SM; Cao L; Figg WD; Donahue RN; Hassan R; Pastan I; Trepel JB; Alewine C
Cancer Med; 2023 Feb; 12(4):4236-4249. PubMed ID: 36208017
[TBL] [Abstract][Full Text] [Related]
6. Anti-drug antibodies to LMB-100 are enhanced by mAbs targeting OX40 and CTLA4 but not by mAbs targeting PD1 or PDL-1.
Mazor R; King E; Pastan I
Cell Immunol; 2018 Dec; 334():38-41. PubMed ID: 30213644
[TBL] [Abstract][Full Text] [Related]
7. Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
El-Behaedi S; Landsman R; Rudloff M; Kolyvas E; Albalawy R; Zhang X; Bera T; Collins K; Kozlov S; Alewine C
Toxins (Basel); 2018 Oct; 10(11):. PubMed ID: 30384408
[TBL] [Abstract][Full Text] [Related]
8. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models.
Jiang Q; Ghafoor A; Mian I; Rathkey D; Thomas A; Alewine C; Sengupta M; Ahlman MA; Zhang J; Morrow B; Steinberg SM; Pastan I; Hassan R
Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32611684
[TBL] [Abstract][Full Text] [Related]
9. Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures.
Liu W; Tai CH; Liu X; Pastan I
Proc Natl Acad Sci U S A; 2022 Nov; 119(48):e2214928119. PubMed ID: 36409889
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors.
Hagerty BL; Pegna GJ; Xu J; Tai CH; Alewine C
Biomolecules; 2020 Jun; 10(7):. PubMed ID: 32605175
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies.
Kreitman RJ; Wilson WH; White JD; Stetler-Stevenson M; Jaffe ES; Giardina S; Waldmann TA; Pastan I
J Clin Oncol; 2000 Apr; 18(8):1622-36. PubMed ID: 10764422
[TBL] [Abstract][Full Text] [Related]
12. Panbinostat decreases cFLIP and enhances killing of cancer cells by immunotoxin LMB-100 by stimulating the extrinsic apoptotic pathway.
Liu XF; Zhou Q; Hassan R; Pastan I
Oncotarget; 2017 Oct; 8(50):87307-87316. PubMed ID: 29152082
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1.
Hassan R; Williams-Gould J; Watson T; Pai-Scherf L; Pastan I
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):16-8. PubMed ID: 14734446
[TBL] [Abstract][Full Text] [Related]
14. Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity.
Kreitman RJ; Stetler-Stevenson M; Jaffe ES; Conlon KC; Steinberg SM; Wilson W; Waldmann TA; Pastan I
Clin Cancer Res; 2016 Jan; 22(2):310-8. PubMed ID: 26350263
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.
Mazor R; Zhang J; Xiang L; Addissie S; Awuah P; Beers R; Hassan R; Pastan I
Mol Cancer Ther; 2015 Dec; 14(12):2789-96. PubMed ID: 26443804
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of a novel anti-mesothelin immunotoxin based on a single domain antibody as the targeting ligand.
Li Q; Li W; Xu K; Xing Y; Ding Y; Jing Z; Wang X; Hong Z
Int J Pharm; 2021 Jun; 602():120647. PubMed ID: 33915185
[TBL] [Abstract][Full Text] [Related]
17. Generation of a Transgenic BALB/c Mouse Line With Selective Expression of Human Mesothelin in Thyroid Gland: Application in Mesothelin-targeted Immunotherapy.
Bera TK; Liu W; Leshem J; King E; Kozlov S; Pastan I
J Immunother; 2019 May; 42(4):119-125. PubMed ID: 30933045
[TBL] [Abstract][Full Text] [Related]
18. Anti-Mesothelin Recombinant Immunotoxin Therapy for Colorectal Cancer.
Cerise A; Bera TK; Liu X; Wei J; Pastan I
Clin Colorectal Cancer; 2019 Sep; 18(3):192-199.e1. PubMed ID: 31345777
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of TNF-alpha produced by Kupffer cells protects against the nonspecific liver toxicity of immunotoxin anti-Tac(Fv)-PE38, LMB-2.
Onda M; Willingham M; Wang QC; Kreitman RJ; Tsutsumi Y; Nagata S; Pastan I
J Immunol; 2000 Dec; 165(12):7150-6. PubMed ID: 11120846
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
